Amgen Inc. Stock Falls Wednesday, Still Outperforms Market

Spectrum Pharmaceuticals Inc

Change company Symbol lookup

Select an option...

SPPI Spectrum Pharmaceuticals Inc

FDBC Fidelity D&D Bancorp Inc

$BUKCHET Bloomberg Coffee Subindex Euro

BMY Bristol-Myers Squibb Co

MLGO MicroAlgo Inc

FRST Primis Financial Corp

VII 7GC & Holdings Co Inc

PEBO Peoples Bancorp Inc

BIOAF Bioasis Technologies Inc

NRGOF Newrange Gold Corp

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Biotechnology | Small Cap Value

Company profile

Spectrum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on acquiring, developing, and commercializing targeted oncology therapies. The Company's product portfolio consists of in-development drug products for the treatment of cancer patients. The Company's pipeline products include Eflapegrastim and Poziotinib. The Eflapegrastim is a long-acting granulocyte colony-stimulating factor (G-CSF) for chemotherapy-induced neutropenia. Poziotinib is a, pan-HER inhibitor that irreversibly blocks signaling through the Epidermal Growth Factor Receptor (EGFR) family of tyrosine-kinase receptors, including HER1 (erbB1; EGFR), HER2 (erbB2), HER4 (erbB4), and HER receptor mutations. The Eflapegrastim employs a LAPSCOVERY technology to enhance the duration of therapeutic effects and reduce the frequency of administration.

Amgen Inc. Stock Falls Wednesday, Still Outperforms Market

4:36 pm ET November 9, 2022 (MarketWatch) Print

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Amgen Inc. (AMGN) slipped 0.94% to $289.65 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index falling 2.08% to 3,748.57 and Dow Jones Industrial Average falling 1.95% to 32,513.94. The stock's fall snapped a three-day winning streak. Amgen Inc. closed $7.02 below its 52-week high ($296.67), which the company reached on November 8th.

The stock demonstrated a mixed performance when compared to some of its competitors Wednesday, as Johnson & Johnson (JNJ) fell 0.80% to $172.45, Roche Holding AG Part. Cert. rose 0.19% to $325.98, and Pfizer Inc. (PFE) fell 1.33% to $46.72. Trading volume (3.5 M) eclipsed its 50-day average volume of 2.8 M.

Data source: Dow Jones Market Data, FactSet. Data compiled November 9, 2022.

(END) Dow Jones Newswires

November 09, 2022 16:36 ET (21:36 GMT)